Index

A

AAV. *See* Adeno-associated virus
Adaptive immunity, CRISPR function in bacteria, 2–3
Adeno-associated virus (AAV), delivery of CRISPR–Cas in mammalian cells
  cloning, 59–61
  gene targeting, 64
  genome modification, 63
  materials, 57–59
  overview, 57
  recipes, 65–68
  troubleshooting, 64–65
  virus production
    buffer exchange and concentration, 62
    cell culture, 61
    iodixanol density gradient centrifugation, 61–62
    titering, 62

B

Bacterial lipoprotein (BLP), Cas9 in repression, 7–8
BLP. *See* Bacterial lipoprotein

C

Cas
  Cas9
    bacteria functions, 7–8
    crRNA maturation mediation, 4–5
    deactivated Cas9 for CRISPRa or CRISPRi
      expression vector preparation, 167
      lentiviral packaging, 167–168
      transduction, 168–169
    guide sequences. *See* Guide RNA
    nuclease-deficient protein, 10
    spacer acquisition, 6–7
    target interference, 5–6
    target sequence specificity, 10–11
    tracrRNA interactions, 20–22
  Cas9–gRNA ortholog characterization
    applications, 33
    orthogonality value, 32–33
    overview, 31–33
    protospacer adjacent motif characterization for Cas9 orthologs
      high-throughput sequencing and analysis, 37–38
      materials, 35–36
      plasmid construction, 36–37
      sequences by bacteria species, 33
      validation of sequences, 38
    putative protein identification, 32
  crRNA interactions, 4
  crystal structures, 2–3
  isoforms in CRISPR systems, 3–4
  nuclease activity, 3
Cell fate, reprogramming with CRISPRa or CRISPRi, 162
CFTR. *See* Cystic fibrosis transmembrane regulator
CRISPRa
  applications, 170–171
  cell fate reprogramming, 162
  deactivated Cas9
    expression vector preparation, 167
    lentiviral packaging, 167–168
  gene expression analysis, 169–170
  materials, 163–165
  multiple gene modulation, 161
  noncoding RNA gene targeting, 161
  principles, 159–161
  recipes, 171
  single guide RNA
    design, 166
    generation, 166–167
    target selection, 165
  transduction, 168–169
CRISPR–Cas
  activation. *See* CRISPRa
  adeno-associated virus delivery. *See* Adeno-associated virus
  bacteria functions, 2–3, 7–8
  Drosophila melanogaster genome engineering. *See Drosophila melanogaster*
  genetic engineering overview, 8–11, 20–22
  historical perspective, 1–2, 17
  human stem cells. *See* Embryonic stem cell; Induced pluripotent stem cell
  mechanism of action, 2, 17–18, 133–135
  mouse genome editing. *See* Mouse
  optimization
    targeting efficiency, 113–114
    targeting repertoire expansion, 114–115
    zebrafish CRISPR–Cas9 system optimization
      Cas9 mRNA production and injection of guide RNA complex, 123–125
      materials, 117–119
      mutation analysis, 125–130
      recipes, 130
      single guide RNA design and generation, 119–123
  repression. *See* CRISPRi
  Saccharomyces cerevisiae genome engineering. *See Saccharomyces cerevisiae*
  types of systems, 2–4, 17–20
CRISPRi
  cell fate reprogramming, 162
  multiple gene modulation, 161
  noncoding RNA gene targeting, 161
  principles, 159–161
crRNA. *See* Guide RNA
Cystic fibrosis transmembrane regulator (CFTR), mutation repair with CRISPR–Cas, 11

D

ddPCR. *See* Droplet digital polymerase chain reaction
Droplet digital polymerase chain reaction (ddPCR)
  overview, 70
  single–nucleotide substitution detection in induced pluripotent stem cells
    challenges, 69–70
    hydrolysis probe and primer preparation and validation, 74–76
    materials, 73–74
    substitution detection in genomic DNA, 76–77
    troubleshooting, 77
Drosophila melanogaster, CRISPR–Cas9 genome engineering
  delivery overview, 90–91
  donor construct generation
    donor construct generation, 95–96
    homology arm design, 94–95

Drosophila melanogaster, CRISPR–Cas9 genome engineering (*Continued*)
materials, 93–94
recipes, 97
troubleshooting, 96–97
editing event detection
high-resolution melt analysis of indel mutations
data analysis, 100–102
genomic DNA preparation, 99–100
materials, 98–99
polymerase chain reaction, 100
recipes, 104
sequencing, 101, 103
troubleshooting, 103–104
overview, 91
off-target effects, 110–111
overview, 89–90
single guide RNA generation
cloning, 107, 109–110
design, 90, 107–108, 111
materials, 106–107
troubleshooting, 110

E

Embryonic stem cell (ESC), overview of human genome editing, 149–150
ESC. *See* Embryonic stem cell

F

FACS. *See* Fluorescence-activated cell sorting
Fluorescence-activated cell sorting (FACS), stem cell Cas9 transfectants, 156

G

gRNA. *See* Guide RNA
Guide RNA (gRNA)
Cas9 guide sequences
prediction and validation of sequences
boundary confirmation for crRNA and tracrRNA, 28
CRISPR repeat and *cas* prediction in silico, 25–26
materials, 24–25
overview, 24
PAM sequence prediction in silico, 28–29
tracrRNA prediction in silico, 25, 27–28
troubleshooting, 29–30
tracrRNA interactions, 20–22
Cas9–gRNA ortholog characterization. *See* Cas
CRISPRa or CRISPRi single guide RNA
design, 166
generation, 166–167
target selection, 165
Drosophila melanogaster single guide RNA design, 90, 107–108
human guide RNA design and generation
induced pluripotent stem cells, 154
overview, 154
mouse single guide RNA
design, 137, 141
generation, 141
screening of CRISPR–Cas9 with single guide RNA library
negative selection screens, 41
overview, 39–40
positive selection screens, 40–41
principles, 40
virus packaging and cell culture for screens
data analysis, 54
materials, 49–50
overview, 49
packaging vector preparation, 51–53
recipes, 55
screen cell culture and library preparation, 53–54
troubleshooting, 54
single guide RNA
large-scale library construction
library amplification and cloning, 45–46
materials, 43–44
recipes, 47–48
sequence design, 44
transformation, 46
troubleshooting, 47
vector preparation, 45
overview, 20–21, 39
zebrafish single guide RNA
design, 119–120
generation, 120–123

H

HDR. *See* Homology-directed repair
Hepatitis viruses, Cas9 targeting, 11
High-resolution melt analysis (HRMA), indel mutations in *Drosophila melanogaster*
data analysis, 100–102
genomic DNA preparation, 99–100
materials, 98–99
polymerase chain reaction, 100
recipes, 104
sequencing, 101, 103
troubleshooting, 103–104
Historical perspective, CRISPR–Cas, 1–2, 17
HIV. *See* Human immunodeficiency virus
Homology-directed repair (HDR)
Cas9 double-strand break repair, 9, 139
efficiency, 147–148
single-nucleotide substitution detection in induced pluripotent stem cells
challenges, 69–70
droplet digital polymerase chain reaction
hydrolysis probe and primer preparation and validation, 74–76
materials, 73–74
overview, 70
substitution detection in genomic DNA, 76–77
troubleshooting, 77
HRMA. *See* High-resolution melt analysis
Human immunodeficiency virus (HIV), Cas9 targeting, 11

I

Induced pluripotent stem cell (iPSC)
genome editing
prospects, 70–71
human CRISPR–Cas editing
colony expansion, 156–157
fluorescence-activated cell sorting of Cas9 transfectants, 156
guide RNA design and generation, 154
materials, 153–154
overview, 150–151
recipes, 158
screening, 157
transfection, 154–156
troubleshooting, 157
overview, 149–150
single-nucleotide substitution detection in induced pluripotent stem cells
challenges, 69–70
droplet digital polymerase chain reaction
hydrolysis probe and primer preparation and validation, 74–76
materials, 73–74
overview, 70
substitution detection in genomic DNA, 76–77
troubleshooting, 77

Iodixanol density gradient centrifugation. *See* Adeno-associated virus
iPSC. *See* Induced pluripotent stem cell

L

Lentivirus, packaging of deactivated Cas9 for CRISPRa or CRISPRi, 167–168

M

Mouse, CRISPR–Cas9 genome editing
  applications
    gene knockout through indel generation, 135
    large deletions, 135–136
    large insertions, 136–137
    point mutations, 135
    small insertions, 135
  Cas9 mRNA production, 142–143
  donor design, 141–142
  donor DNA purification, 144
  efficiency, 147–148
  embryo transfer, 146
  genotyping, 146–147
  materials, 139–141
  mechanisms, 133–135
  microinjection
    sample preparation, 144
    technique, 145–146
    zygote preparation, 144–145
  prospects, 137
  recipes, 148
  screening considerations, 137
  single guide RNA
    design, 137, 141
    generation, 141
  troubleshooting, 147
Mut–Seq. *See* Zebrafish

N

NHEJ. *See* Nonhomologous end joining
Nonhomologous end joining (NHEJ), Cas9 double-strand break repair, 9, 134

P

p300, fusion with nuclease-deficient Cas9, 10
PAM. *See* Protospacer adjacent motif
Polymerase chain reaction. *See* Droplet digital polymerase chain reaction
Protospacer adjacent motif (PAM), 4–6, 9, 22, 113
  characterization for Cas9 orthologs
    high-throughput sequencing and analysis, 37–38
    materials, 35–36
    plasmid construction, 36–37
    sequences by bacteria species, 33
    validation of sequences, 38
  mutation generation in yeast
    within 20 nucleotides 5′ of PAM sequence, 83
    within 60 nucleotides 5′ of PAM sequence, 83–84
  sequence prediction in silico, 28–29

R

Repression. *See* CRISPRi

S

Saccharomyces cerevisiae, CRISPR–Cas9 genome engineering
  competent cell preparation, 81–82
  cotransformation of pCAS and linear DNA, 85
  double-stranded DNA repair
    DNA barcode assembly, 83
    error-prone polymerase chain reaction for DNA library generation, 84–85
  mutation generation
    within 20 nucleotides 5′ of PAM sequence, 83
    within 60 nucleotides 5′ of PAM sequence, 83–84
  principles, 82
  synthetic gene construct generation for DNA assembly in vivo, 84
  guide sequence cloning, 80–81
  materials, 79–80
  overview, 79, 85–86
  recipes, 86
Single guide RNA. *See* Guide RNA
Single-nucleotide substitutions. *See* Homology-directed repair
Spacer acquisition
  Cas nuclease role, 3
  Cas9-dependent CRISPR systems, 6–7
  CRISPR-mediated interference, 2, 17–18
Stem cells. *See* Embryonic stem cell; Induced pluripotent stem cell

T

tracrRNA. *See* Guide RNA

Z

Zebrafish, CRISPR–Cas9 system optimization
  Cas9
    injection of guide RNA complex, 125
    mRNA production, 123–125
  materials, 117–119
  mutation analysis
    fragment analysis, 125–127
    Mut–Seq, 127–130
  recipes, 130
  single guide RNA
    design, 119–120
    generation, 120–123